Medtronic plc. (NYSE:MDT) Opens First Canadian Medtronic Resource Centre To Serve Diabetics

Medtronic plc. (NYSE:MDT) Opens First Canadian Medtronic Resource Centre To Serve Diabetics

Patients living with diabetes in Surrey, British Columbia and the surrounding area will now have easier access to support, education and other resources. This is as a result of the opening of the new Medtronic Resource Centre by Medtronic Canada, a subsidiary of Medtronic plc. Ordinary Shares (NYSE:MDT).  The new center comes at a time when the numbers of type 1 and type 2 diabetes patients who rely on an insulin pump and continuous glucose monitoring are growing.

Medtronic says that it aims at helping in managing the different elements of diabetes, which will result in improved outcomes in the community.

The center is seen as a real-world solution to a real-world problem

Records have it that the global diabetes market is likely to reach $155 billion by 2021. Apart from tapping into an untapped market of Canada, Medtronic will also be trying to reduce these numbers through its new center, which will also aid in reducing long-term complications in patients.

The center has been regarded by many as a real-world solution to a real-world problem. Medtronic Canada’s Diabetes Group director, Laura Cameron notes, “To provide greater freedom and better health, Medtronic is dedicated to helping to reduce long-term complications associated with diabetes, and reduce the burden for them, and for the healthcare system.”

But Medtronic has other developments as well

Medtronic, which is one of the world’s largest medical technology, services, and solutions companies employs close to 88,000 people worldwide. Its presence is in over 160 countries and its main focus is to help in restoring health and extending life for millions of people around the world.

However, the new center is just the tip of the iceberg of the many developments that the company is establishing. In the recent past, it has launched MiniMed 670G system, which will also help in simplifying the management of diabetes; thanks to its advanced smart algorithms. The Hybrid Closed Loop Insulin delivery system will be handy in managing Type I diabetic patients.

Meanwhile, Medtronic’s shares closed at $87.65 witnessing an increase of $0.44 or 0.50%.